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ABSTRACT
Background – It is known that personality has an influence on the outcome of mental state disorders, but de-
tailed studies on its long‐term impact are few. We examined the influence of personality status on the 8‐year
outcome of health anxiety and its relationship to the effects of cognitive behaviour therapy in a randomized con-
trolled trial.
Aims – This study aims to examine both the usefulness of the diagnosis of personality disorder and an additional
measure of pathological dependence, in predicting the outcome of medical patients with health anxiety treated
with cognitive behaviour therapy. Because the influence of personality is often shown in the long term, these as-
sessments covered the period of 8 years after randomization. An additional aim is to examine the costs of different
levels of personality dysfunction in each treatment group.
Method – Personality dysfunction, using both ICD‐10 and ICD‐11 classifications of severity, was assessed at
baseline by interview in a randomized controlled trial. Patients were also assessed for pathological dependence
using the Dependent Personality Questionnaire, also scored along a severity dimension. Four hundred
forty‐four patients from medical clinics with pathological health anxiety were treated with a modified form of cog-
nitive behaviour therapy for health anxiety (CBT‐HA) or standard care. Total costs over follow‐up were cal-
culated from hospital data and compared by personality group.
Results – At baseline, 381 (86%) had some personality dysfunction, mainly at the lower level of personality
difficulty (not formally a disorder). One hundred eighty four (41%) had a personality disorder. A similar pro-
portion was found with regard to dependent personality. Using the ICD‐10 classification, 153 patients (34.6%)
had a personality disorder, with 83 (54.2%) having anxious or dependent personality disorder, 20 (13.1%)
having an anankastic disorder, but also with 66 (43.1%) having mixed disorder. During initial treatment, those
with personality disorder adhered more closely to CBT‐HA, and after 8 years, they had a significantly better
outcome than those with personality difficulty and no personality disorder (p < 0.002). Similar results were
found in those scoring high on the Dependent Personality Questionnaire. All these differences increased over
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the follow‐up period. Costs were similar in all groups but were somewhat higher in the CBT‐HA one; this find-
ing is hypothesised to be due to fuller hospital treatment once health anxiety is discounted.
Conclusion – Personality disorder in people with health anxiety, particularly in those who have anxious and
dependent traits, reinforces the benefits of cognitive behaviour therapy, particularly in the longer term.
© 2020 The Authors Personality and Mental Health Published by John Wiley & Sons Ltd
Background
There has been considerable dispute about the im-
pact of personality disorder on the outcome of
other psychiatric disorders in research studies car-
ried out over the past 30 years. This has been most
aired with depression, with some studies suggesting
that the presence of personality disorder has no ef-
fect on the outcome of depressive disorders1–3 and
others suggesting it has a negative effect.4–6 The
balance of evidence at present, in the largest
meta‐analysis to date, suggests that a negative ef-
fect is the most likely.6 A similar negative effect
has been noted with anxiety.7 There are also con-
flicting data of the influence of personality disor-
der on specific treatments for mood disorders,
ranging from no differences to better results with
drug or psychological treatment depending on
the population chosen.8–10 There is one small
study hinting that Cluster A personality disorder
improves outcome in cognitive behaviour therapy
for depression.11
So it can fairly be said that there is a degree of
uncertainty about both the nature of the relation-
ship between personality and affective disorders of
all kinds. But the degree of interest in the subject
is relevant to practice. Until recently, the clear ev-
idence that a significant minority (if not a major-
ity) of all patients presenting in psychiatric
practice have a personality disorder12,13 has been
ignored when selecting treatment. The extra in-
formation provided by personality status should
help both in selecting treatment and introducing
appropriate management for personality dysfunc-
tion and for the prime disorder.
In planning a large therapeutic trial of adapted
cognitive behaviour therapy for health anxiety
(CBT‐HA), we therefore felt it appropriate to in-
clude personality assessment and clinical ratings.
Because little was known about the long‐term
outcome of health anxiety, it was judged that
protracted follow‐up was desirable.
Method
Study design
The Cognitive behaviour therapy for Health Anx-
iety in Medical Patients (CHAMP) study was a
pragmatic randomized controlled trial of cognitive
behaviour therapy adapted for health anxiety
(CBT‐HA). Patients seen in medical clinics were
randomized to CBT‐HA or standard clinic care
if they scored at or above a threshold for patholog-
ical health anxiety.14 Full details of the methodol-
ogy of the trial are given elsewhere.15,16 In brief,
the study recruited patients attending medical
out‐patient clinics and randomized them either
to 5–10 sessions of CBT‐HA (from initially naïve
but trained therapists) or to standard care in pri-
mary and secondary care clinics.16 The
out‐patients were attending cardiology, endocrine,
gastroenterology, neurology and respiratory medi-
cine clinics in six hospitals in London, Middlesex
and North Nottinghamshire. The consenting pa-
tients completed the Short Health Anxiety Inven-
tory (SHAI),14 a self‐rated scale of 14 questions
with a score range of 0–42. Those that scored 20
or more on the scale (a point shown to discrimi-
nate between those who have persistent worries
over health and those who show normal
variation14,15) were invited to take part in the
trial, and an information sheet about the study
was given. In addition, the initial assessment in-
volved asking key questions from the Structured
Clinical Interview for DSM‐IV17 covering the for-
mal diagnosis of hypochondriasis. Patients were
included if aged between 16 and 75 years, living
in the area covered by the hospital, with sufficient
understanding of English to read and complete
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study questionnaires and interviews, and who had
given written consent for audio‐taping of 50% of
treatment sessions, and access to their medical
records.15 All those who satisfied the inclusion
criteria and hypochondriasis diagnosis were then
offered randomization to the trial, and if they
agreed, full baseline assessments were completed,
and written informed consent obtained.
The study was approved by the North Notting-
ham Ethics Committee (08/H0403/56) before the
start of data collection.
Assessments of symptomatology and personality
The primary outcome measure was the change
from baseline score for the SHAI14 at 1 year after
randomization. Secondary measures included gen-
eralized anxiety and depression using the Hospital
Anxiety and Depression Scale (HADS‐A and
HADS‐D),18 health‐related quality of life using
the short Euroqol measure (EQ‐5D)19 and social
function using the Social Functioning Question-
naire (SFQ).20 All measures were recorded at
baseline, 6 months, 12 months, 24 months, 5 years
and 8 years (with the exception of the HAI which
was also recorded at 3 months). Assessments were
made completely independently by research assis-
tants. Service use data for the economic evalua-
tion were collected at baseline, 6 months,
12 months, 24 months, 5 years and 8 years
follow‐up using hospital records only in the latter
period.
Personality assessment was carried out by two
methods. The first involved the administration of
the quick version of the Personality Assessment
Schedule (PAS‐Q),21 which records both the se-
verity and the type of personality disorder using a
four‐point scale. This contains a series of screen-
ing questions for each area of personality dysfunc-
tion and those that score positive lead to further
questions. It takes about 30–45 min to administer.
The PAS‐Q was scored by a trained research assis-
tant at the last part of the baseline interview, and
the assessment forms include both numerical rat-
ings and written comments amplifying each of
the sections. During the course of the study, the
Working Group for the Reclassification of Person-
ality Disorder in ICD‐11 completed its initial
work on a new system of classification based on se-
verity criteria (April 2010).22 Shortly afterwards,
R. S., P. T. and G. L. reclassified the personality
status of the patients in the study to convert them
to ICD‐11 severity equivalents by examining the
PAS‐Q data and written comments22 and by
interviewing assessors if the data were not clear.
For 30 of the assessments, R. S. and P. T. com-
pleted independent assessments and achieved a
good level of agreement (kappa ¼ 0.85).
The second part of personality assessment was
the administration of the Dependent Personality
Questionnaire (DPQ).23 This scale has eight ques-
tions, with a range of scores between 0 and 24, has
already been shown to be temporally stable and
has an accurate measure of personality disorder.24
It was included as it is generally desirable to have
self‐report and observer assessments of personality
to gain a comprehensive picture.25 To produce
equivalence with the ICD‐11 severity classifica-
tion, a similar severity scale was created with the
DPQ scores [0–6, no dependent personality dys-
function, 7–11, dependent personality difficulty,
12–16, mild dependent personality disorder, ≥17,
moderate (rarely with severe personality
disorder)].
Randomization and masking
Randomization to the two treatment groups was
carried out by an independently operated comput-
erized system (Open‐CDMS), with a
computer‐generated random sequence using block
randomization with varying block sizes of four and
six. The allocation sequence was not available to
any member of the research team until databases
had been completed and locked.
Statistical analysis
The calculation of the sample size for the main
study has been described previously15; it was
powered to assess the superiority of CBT‐HA over
standard care. The current study was a secondary
analysis of the outcomes for different levels of se-
verity of personality disturbance, and so no formal
sample size calculation was performed.
The primary endpoint (SHAI) was analysed
using a mixed model with time, treatment group
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Personality impact on outcome of CBT in health anxiety
© 2020 The Authors Personality and Mental Health Published by John Wiley & Sons Ltd (2020)
DOI: 10.1002/pmh
and time × treatment interaction as fixed effects,
baseline measurement as covariate, and patient
as random effect by personality severity group in
order to test for the first hypothesis, that the
CBT‐HA would be less effective in participants
with a personality disorder. The treatment differ-
ences between the four ICD‐11 personality and
dependent personality groups were calculated at
each time point [3 m (SHAI only), 6 months,
1 year, 2 years, 5 years and 8 years]. Other second-
ary endpoints were analysed in the same way. All
analyses were based on the intention‐to‐treat
principle.
Economic analysis
The economic evaluation is described in detail
elsewhere.15 Total costs were calculated by com-
bining the hospital use from electronic records
with nationally applicable unit costs.26–28 Costs
were calculated and analysed in UK pound ster-
ling for the financial year 2008–2009 and were
discounted in the second and subsequent years at
a rate of 3.5% as recommended by the National
Institute for Health and Clinical Excellence.29
Complete case analysis was used for the economic
evaluation.15 The second hypothesis that partici-
pants with personality disorder would have in-
creased costs was explored through the
examination of differences in costs over the
8‐year follow‐up period between ICD‐11 and de-
pendent personality groups. Analysis was per-
formed using ordinary least squares regression as
is appropriate for cost data, with the robustness
of the tests confirmed using bias‐corrected,
non‐parametric bootstrapping.30,31 Differences in
all analyses were adjusted for baseline costs and
randomized group.
Results
At baseline, 219 patients were randomized to
CBT‐HA and 225 to standard care; 77% had an
established physical diagnosis at baseline. Attri-
tion rates and follow‐up using the CONSORT
procedure at 5 years have been reported earlier.32
At 8 years, 308 patients provided data.
Personality status
Using the ICD‐10 classification derived from the
PAS‐Q, 153 patients (34.6%) had a personality
disorder, with 83 (54.2%) having anxious or de-
pendent personality disorder, 20 (13.1%) having
an anankastic disorder, but a larger proportion,
66 (43.1%) having mixed disorder, mainly of dis-
orders within the original emotionally unstable
of ICD‐11 in 201122 but now called the negative
affectivity domain of the new ICD‐11
classification.33 On the severity scale, most people
recruited had some personality dysfunction. Only
63 (14.2%) had no personality dysfunction using
the ICD‐11 classification, but in keeping with
other findings,34 197 (44.3%) had personality dif-
ficulty (a sub‐threshold condition not qualifying
for disorder). Only three people assessed had se-
vere personality disorder, and so they were in-
cluded in the moderate group. The distribution
of personality groups showed equivalent propor-
tions for the ICD‐11 and dependent categories,
with greater baseline levels of anxiety and depres-
sion and more social dysfunction in the more per-
sonality disordered groups (Table 1). There was a
gender difference with those with greater depen-
dence being more likely to be female.
There were no differences in total costs at
baseline.
Treatment differences by personality status
The 8‐year outcome data separated by personality
status showed clear separation in both ICD‐11
and dependent groups (n ¼ 308). Contrary to
our initial hypotheses,15 the results showed that
patients with general personality dysfunction and
dependent disorder had significantly better out-
comes than those with personality difficulty and
no personality dysfunction. This was shown uni-
versally in terms of the primary outcome, change
in HAI score (Figures 1 and 2), generalized anxi-
ety (HADS‐A), depression (HADS‐D) and social
function (SFQ), with the most significant differ-
ences found in people with the most severe per-
sonality disorders and greater dependent
personalities (Tables 2 and 3). For almost all these
measures, the group that showed the least group
differences was the one with no personality
Peter Tyrer et al.
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dysfunction and that showing the largest differ-
ences was the most personality disordered group.
The findings showed that over 8 years, all groups
improved with the exception of that with more se-
vere personality disorders in standard care (Fig-
ure 2, Tables 2 and 3), and it was this failure to
improve that created the larger differences at
8 years (Table 3).
Total hospital costs over 8‐year follow‐up by
randomized group and personality score are de-
tailed in Table 4. Costs were generally higher in
the CBT group but broadly similar across personal-
ity groups, but the largest differences were shown
in the more severe personality disordered patients,
with CBT‐HA showing greater costs. Regression
analysis suggested that the differences in cost be-
tween personality groups were not significant.
Number of treatment sessions
In both ICD‐11 and dependent personality
groups, the patients with the most severe personal-
ity disturbance received more sessions of treatment
than others (Table 5). As the trial allowed flexi-
bility in the number of sessions, with the
expectation that six would normally be the maxi-
mum, this variation was unexpected.
Discussion
The challenging finding of this study was that
both the hypotheses concerning personality status
were contradicted. People with no personality dys-
function did not benefit from health anxiety
adapted cognitive behaviour therapy (CBT‐HA)
in the early stages of the study and at no point
were their symptoms and functioning superior to
standard care. By contrast, all those with some
personality dysfunction showed selective benefit
from CBT‐HA at some point during the
follow‐up period, with the maximum being shown
at 8 years in the most disordered group.
The statistics here are robust, with good con-
cordance between self‐rated and observer assess-
ments, and it is difficult to find an alternative
explanation that could explain the results. All
data were collected by research workers who had
no knowledge of baseline personality status, and
bias in assessment can be discounted.
Figure 1: Mean change in short health anxiety inventory (HAI) score in patients with no personality disorder (ICD‐11 levels
0 and 1) and personality disorder (levels 2–4) over 8 years [Colour figure can be viewed at wileyonlinelibrary.com]
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The screening threshold for health anxiety was
a score of 20 points on the Short Health Anxiety
Inventory (HAI), and it could be argued that this
was too low. This score equates to around 62 on
the long version of the HAI, and a score of 67 on
the long HAI has been found to be a good cut‐off
point for discriminating between normal and path-
ological anxiety.35 But it is also fair to add that the
SHAI was a screening instrument only and that
many patients with high scores did not enter the
trial, including a proportion who did not have
DSM‐IV hypochondriacal disorder.16
If we assume that the results reflect some ad-
vantage of personality dysfunction when receiving
CBT‐HA, it is worth examining how this could
have come about. Certainly, the old standard re-
quirement in for many former mental health tri-
als—patients with personality disorder will be
excluded—would not have been appropriate here.
It is also important to note that the more severely
personality disordered patients treated with
CBT‐HA did not achieve a higher level of overall
improvement than other groups; the difference in
outcome was a consequence of poor outcome in
this group in standard care.
The greater number of sessions in the personal-
ity disordered patients is relevant here. The flexi-
bility allowed in the trial allowed extra sessions
to be given, and it is likely that this extra input,
combined with lower levels of drop‐out, had an
impact on outcome. It is also possible that
CBT‐HA was treating personality disturbance
and health anxiety, as Hedman et al.36 have
claimed. It has long been known that personality
disturbance is common in hypochondriasis, and a
case has been made for the identification of a
Figure 2: Mean changes in HAI score in patients separated by scores on the dependent personality questionnaire (DPQ) over
8 years. Level 0¼ 0–6, Level 1¼ 7–11, Level 2¼ 12–16, Level 3¼ ≥17 [Colour figure can be viewed at wileyonlinelibrary.com]
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separate condition, hypochondriacal personality
disorder, and a condition with a relatively poor
outcome.37,38
As cognitive therapy is quite capable of em-
bracing personality disturbance effectively,39 it is
also quite possible that CBT‐HA includes a per-
sonality disorder relieving component, particularly
as the features of hypochondriacal personality dis-
order are so clearly linked to health anxiety symp-
toms. However, a study of CBT in panic disorder
showed no such benefit in those with similar per-
sonality disturbance as in the CHAMP study.40
Economic aspects
The cost data do not show any savings for CBT‐
HA, and indeed, the total costs are higher in all
those treated. This contradicts our earlier hypoth-
eses about cost savings and also those reported in
all previous studies of psychological treatments
for health anxiety.24,41–43 The explanation for this
almost certainly lies in the high level of medical
co‐morbidity of the participants in the study and
in the absence of primary care costs, as this is
where health anxiety becomes most expensive.
This was not the case in other samples. For exam-
ple, in a study using very similar methodology to
the CHAMP study, and yielding very similar re-
sults in terms of clinical benefit, there was a net
monetary benefit of £3 164 per patient in the
treatment arm of the study, with total costs of
£2 197 being 48% more than standard care.43
The mean cost of in‐patient care in this study
was £22 in the CBT‐HA group, a tiny fraction
of the numbers reported in this paper, in which
most of the patients had medical co‐morbidity.
Nonetheless, we still have a set of differences in
favour of standard care in the CHAMP study at
8 years (Table 5) that needs explaining. Although
these are not significant, it is fair to add that very
large samples indeed are needed to show signifi-
cance in cost‐effectiveness studies, so here, it is
justified to comment. Possible explanations in-
clude possible unreliability of hospital data and in-
tensity of health anxiety not being related to
costs.44
A more plausible explanation is that improve-
ment in health anxiety allows medical staff to
make a better evaluation of medical symptoms.
Thus, those who have recovered from health anx-
iety are treated more appropriately and more rele-
vant medical illness identified. In the CHAMP
study, there was no difference in the mortality of
patients in each treatment group overall, but those
in standard care had great mortality in the early
years of the study.16 These data support this hy-
pothesis, but it has to be a speculative one.
Implications
What clinical and theoretical messages can we
conclude from these findings? In clinical practice,
a strong case can be made for physicians and their
colleagues in general hospitals to be more aware of
health anxiety in their practice,45 but can we add
personality to health anxiety as well? Probably
not, but the good physician, with sensitive tenta-
cles, will be able to pick up important aspects of
personality from a clinical examination. In some
centres, particularly those treating cancer, screen-
ing instruments are used for depression and been
found to be of value. But this is partly because un-
detected depression is still eminently treatable,
personality disorder less so.
But we cannot ignore the tangled web that per-
sonality weaves around health anxiety. Whether it
is an intimate part of the syndrome or not, it
clearly has an influence on outcome. Its assess-
ment in the CHAMP study might have been
thought a capricious addition to the many instru-
ments selected, but it was clearly not, and both
the patients and the many research assistants in-
volved in the baseline assessments often
commented that this was the most interesting
component of the enquiry. The question posed
by Hedman et al.34 remains, does successful psy-
chological treatment improve personality diffi-
culty and disorder, and if so, how? If personality
status had been recorded after 8 years, we might
have had at least a partial answer to that question,
but at present, it must remain in the air.
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